MYAM
ALXN

Meiji Yasuda Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Meiji Yasuda Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,043
Closed -$559K – 534
2021
Q2 		$559K Sell
3,043
-100
-3% -$17.2K 0.03% 354
2021
Q1 		$481K Buy
3,143
+990
+46% +$153K 0.04% 353
2020
Q4 		$336K Buy
2,153
+25
+1% +$3.21K 0.03% 321
2020
Q3 		$244K Sell
2,128
-3,005
-59% -$324K 0.03% 338
2020
Q2 		$576K Buy
5,133
+1,470
+40% +$156K 0.05% 267
2020
Q1 		$329K Sell
3,663
-2,030
-36% -$199K 0.06% 222
2019
Q4 		$616K Buy
5,693
+140
+3% +$15K 0.05% 308
2019
Q3 		$544K Hold
5,553
– – 0.04% 345
2019
Q2 		$727K Sell
5,553
-2,812
-34% -$362K 0.06% 311
2019
Q1 		$1.13M Buy
8,365
+34
+0.4% +$4.23K 0.1% 224
2018
Q4 		$811K Buy
8,331
+3,758
+82% +$444K 0.08% 274
2018
Q3 		$636K Hold
4,573
– – 0.05% 322
2018
Q2 		$568K Sell
4,573
-1,900
-29% -$222K 0.05% 342
2018
Q1 		$721K Buy
6,473
+280
+5% +$33.5K 0.07% 298
2017
Q4 		$741K Buy
6,193
+1,900
+44% +$231K 0.07% 290
2017
Q3 		$602K Buy
4,293
+1,365
+47% +$185K 0.06% 321
2017
Q2 		$356K Hold
2,928
– – 0.04% 410
2017
Q1 		$355K Hold
2,928
– – 0.04% 407
2016
Q4 		$358K Sell
2,928
-995
-25% -$122K 0.04% 393
2016
Q3 		$481K Buy
3,923
+790
+25% +$102K 0.06% 320
2016
Q2 		$366K Buy
3,133
+1,420
+83% +$201K 0.05% 343
2016
Q1 		$238K Sell
1,713
-160
-9% -$23.5K 0.05% 309
2015
Q4 		$357K Sell
1,873
-260
-12% -$45.4K 0.08% 244
2015
Q3 		$334K Sell
2,133
-780
-27% -$142K 0.08% 246
2015
Q2 		$527K Sell
2,913
-840
-22% -$145K 0.12% 173
2015
Q1 		$650K Sell
3,753
-295
-7% -$53.4K 0.16% 149
2014
Q4 		$749K Sell
4,048
-150
-4% -$27.8K 0.18% 137
2014
Q3 		$696K Buy
4,198
+1,330
+46% +$218K 0.16% 139
2014
Q2 		$448K Sell
2,868
-600
-17% -$94.7K 0.09% 211
2014
Q1 		$528K Buy
3,468
+660
+24% +$105K 0.11% 186
2013
Q4 		$373K Sell
2,808
-50
-2% -$6K 0.08% 231
2013
Q3 		$332K Buy
2,858
+408
+17% +$44.8K 0.08% 240
2013
Q2 		$230K Buy
+2,450
New +$236K 0.05% 305

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Meiji Yasuda Asset Management's ALXN Position: Q3 2021 in Review

Meiji Yasuda Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,043 shares — an estimated $559K sold.

Meiji Yasuda Asset Management first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $1.13M in Q1 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Meiji Yasuda Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Meiji Yasuda Asset Management sold 3,043 Alexion Pharmaceuticals shares in Q3 2021, an estimated $559K.
  • Meiji Yasuda Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Meiji Yasuda Asset Management's Alexion Pharmaceuticals position peaked at $1.13M in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Meiji Yasuda Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.